Related Experiment Video
Updated: Aug 17, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Continuous toxicity monitoring in phase II trials in oncology
Anastasia Ivanova1, Bahjat F Qaqish, Michael J Schell
1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7420, USA. aivanova@bios.unc.edu
Abstract:
The goal of a phase II trial in oncology is to evaluate the efficacy of a new therapy. The dose investigated in a phase II trial is usually an estimate of a maximum-tolerated dose obtained in a preceding phase I trial. Because this estimate is imprecise, stopping rules for toxicity are used in many phase II trials. We give recommendations on how to construct stopping rules to monitor toxicity continuously. A table is provided from which Pocock stopping boundaries can be easily obtained for a range of toxicity rates and sample sizes. Estimation of the probability of toxicity and response is also discussed.
Related Concept Videos
Toxicity Testing in Animals
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Toxicokinetics: Overview
Therapeutic Drug Monitoring: Drug Analysis Methods

